The real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: a Turkish Oncology Group Study
Yükleniyor...
Dosyalar
Tarih
2021
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Springer
Erişim Hakkı
info:eu-repo/semantics/closedAccess
Özet
Introduction Osimertinib, an irreversible third-generation EGFR-TKI, is the standard of care for second-line treatment of T790M-mutant advanced NSCLC patients whose disease progressed after frst-line EGFR-TKI therapy. In this multicenter study, we aimed to determine the real-life efcacy and safety of Osimertinib in pretreated advanced NSCLC patients with T790M mutation. Materials and methods This retrospective trial included advanced T790M-mutant pretreated NSCLC patients who received Osimertinib from 24 diferent centers in Turkey. Primary endpoint was time-to-treatment discontinuation (TTD). Secondary endpoints were objective response rate (ORR), overall survival (OS), and safety. Results Of 163 patients, 68.7% had EGFR exon 19 deletion and 22.7% had exon 21 L858R mutation. Osimertinib was given as second-line treatment in 96 patients (58.9%) and third-line in 48 patients (29.4%). After median of 13-month follow-up, median TTD was 21.6 months with an 82.2% ORR. Estimated median OS was 32.1 months. Grade 3–4 adverse events were seen in 11.7% of the patients. Conclusion Osimertinib is a highly efective option in second- or third-line treatment of NSCLC patients with T790M mutation, with a favorable safety profle.
Açıklama
Anahtar Kelimeler
Osimertinib, Non-small Cell Lung Cancer, EGFR, T790M, Second Line
Kaynak
Journal of Cancer Research and Clinical Oncology
WoS Q Değeri
Q2
Scopus Q Değeri
N/A
Cilt
Sayı
Künye
Hizal, M., Bilgin, B., Paksoy, N., Açıkgöz, Ö., Sezer, A., Gürbüz, M., Ak, N., Yücel, Ş., Ayhan, M., Erol, C., Demirkıran, A., Mandel, N. M., Shbair, A., Gökmen, İ., Başoğlu, T., Paydaş, S., Demiray, A. G., İriağaç, Y., Şakalar, T., Zeynelgil, E., … Şendur, M. (2021). The real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: a Turkish Oncology Group Study. Journal of cancer research and clinical oncology, 10.1007/s00432-021-03748-7. Advance online publication. https://doi.org/10.1007/s00432-021-03748-7
